Survey on the Use of Medicines in Patients with Co-existing Hypertension and Type 2 Diabetes at the Internal Medicine Department of E Hospital in 2020-2022

The study aims to describe the situation of using antihypertensive and hypoglycemic drugs; Initial evaluation of the effectiveness of drug used in the treatment regimen of patients with concomitant hypertension and type 2 diabetes. Methods: a cross-sectional, retrospective study was performed on 179 medical records of patients who had hypertension and type 2 diabetes, examination and treatment at the Internal Medicine Department - Hospital E from April 2020 to December 2022. Information collected from medical records was processed using SPSS 26.0 statistical software. Result: the main groups of hypoglycemic drugs used were metformin (74.9%) and insulin (69,3%). The rate of using multi-drug regimen for diabetes (64.8%) is higher than that of monotherapy, in which the two-drug regimen of insulin and biguanide (metformin) is common (32.4%). The main groups of antihypertensive drugs used were ACE inhibitors and Ca channel blockers (72.6% and 57.5%), 60.3% of patients were treated according to a multi-drug regimen in which combination regimens of 2 groups of Ca channel blockers and ACE inhibitors are common (26.3%). There are no clinically significant interactions between antidiabetic and antihypertensive drugs. The rate of patients who reached the target blood pressure was 83.8%. The rate of patients achieving target blood sugar levels when discharged from the hospital was 40.9%. Conclusion: multi-drug regimen is used more than monotherapy in the treatment of hypertension and diabetes. Most patients reached target blood pressure on discharge, however the number of patients achieving target blood glucose was quite limited . No drug interactions were found between drugs used to lower blood pressure and hypoglycemic drugs.